Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.34
- Piotroski Score 8.00
- Grade Outperform
- Symbol (EXEL)
- Company Exelixis, Inc.
- Price $34.29
- Changes Percentage (0%)
- Change -$0
- Day Low $34.08
- Day High $34.37
- Year High $34.65
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $30.00
- High Stock Price Target $38.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.65
- Trailing P/E Ratio 33.66
- Forward P/E Ratio 33.66
- P/E Growth 33.66
- Net Income $207.77 M
Income Statement
Quarterly
Annual
Latest News of EXEL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Exelixis Shows Rising Price Performance With Jump To 93 RS Rating
Investor's Business Daily's exclusive rating, the Magnificent Seven Stocks, tracks market leadership with a score of 1 to 99. Stocks with an RS Rating of 80 or higher tend to be top market performers....
By Investor's Business Daily | 5 days ago -
Exelon 3Q Net, Revenue Rise Amid Extreme Weather
Exelon exceeded analysts' expectations in the third quarter due to increased electricity usage from hotter weather. The company reported a net income of $707 million and revenue of $6.15 billion, driv...
By MarketWatch | 6 days ago -
Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Exelixis focuses on active molecules generating differentiating clinical data in the GU/GI space, agnostic to modality and deal size. The company leads in synthetic lethality assets with XL-309 and XL...
By Yahoo! Finance | 6 days ago
